A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Stemis™ Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Mesenchymal stem cell therapies (Primary)
- Indications Asthenia
- Focus Adverse reactions
- Sponsors Jyong Biotech
Most Recent Events
- 18 Mar 2026 New trial record